Cephalon distancing Provigil from Plavix
Executive Summary
Cephalon believes that its settlements with four generic manufacturers over patents for the excessive sleepiness therapy Provigil are not comparable to Bristol-Myers Squibb and Sanofi-Aventis' recently rejected settlement with Apotex over Plavix generics. When asked by "The Pink Sheet" whether FTC granted antitrust clearance to the deals, firm responds: "Our case is unrelated to the Bristol-Myers case. Cephalon is not subject to a consent decree that would require FTC approval of settlements. Similarities end at the fact that we both have made settlements with generic companies." The Provigil agreements are subject to antitrust clearance and FTC has expressed concern about the deals (1"The Pink Sheet" May 1, 2006, p. 10)...
You may also be interested in...
Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition
The Federal Trade Commission will not remain complacent as brand and generic companies accelerate the pace and expand the boundaries of settlements, Commissioner Jon Leibowitz said
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.